(Q37916532)

25 August 2017

title

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand (English)

1 reference

25 August 2017

0 references

cervix uterine cancer

1 reference

inferred from title

author

Viroj Tangcharoensathien

8

object named as

Viroj Tangcharoensathien

1 reference

25 August 2017

2

Yot Teerawattananon

1 reference

25 August 2017

3

Sripen Tantivess

1 reference

25 August 2017

5

Arthorn Riewpaiboon

1 reference

25 August 2017

author name string

Naiyana Praditsitthikorn

1

1 reference

25 August 2017

Supon Limwattananon

4

1 reference

25 August 2017

Saibua Chichareon

6

1 reference

25 August 2017

Nantakan Ieumwananonthachai

7

1 reference

25 August 2017

publication date

1 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

29

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

781-806

1 reference

https://scigraph.springernature.com/pub.10.2165/11586560-000000000-00000

25 August 2017

exact match

0 references

cites work

Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Prophylactic HPV vaccines: new interventions for cancer control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Cost-effectiveness of cervical-cancer screening in five developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

EuroQol: the current state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Handling uncertainty in cost-effectiveness models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Modelling the random effects covariance matrix in longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

A guide to cost-effectiveness acceptability curves.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Cost-effectiveness of a potential vaccine for human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Chapter 19: Cost-effectiveness of cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

Population‐Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11586560-000000000-00000

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

21 January 2018

1 reference

12 December 2020

Handling time in economic evaluation studies

1 reference

12 December 2020

The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the national list of essential drugs.

1 reference

12 December 2020

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

1 reference

12 December 2020

Cancer incidence trends in Thailand, 1989-2000.

1 reference

12 December 2020

10.2165/11586560-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1012517862

0 references

1 reference